Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Active as of 2024-12-19 |
Generated Narrative: Citation 267246
version: 2; Last updated: 2024-11-22 19:28:42+0000
Profile: JournalArticleCitation
url: Citation 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
identifier: FEvIR Object Identifier/https://fevir.net/FOI/267246, https://pubmed.ncbi.nlm.nih.gov/11232013, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.44
version: 2.0.0-ballot
title: 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
status: Active
date: 2024-12-19 14:29:51+0000
publisher: HL7 International / Clinical Decision Support
contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss
description:
This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.
| Code | Value[x] |
| Citation Classification Type fevir-platform-use: FEvIR Platform Use | Medline Base |
jurisdiction: World
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
approvalDate: 2001-04-12
lastReviewDate: 2018-11-30
author: Computable Publishing®: MEDLINE-to-FEvIR Converter:
classification
type: Citation Source
classifier: MEDLINE
classification
type: MEDLINE Citation Owner
classifier: National Library of Medicine, Index Section
currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish
statusDate
activity: PubMed Pubstatus of Pubmed
period: ?? --> 2001-03-07 10:00:00+0000
statusDate
activity: PubMed Pubstatus of Medline
period: ?? --> 2001-04-17 10:01:00+0000
statusDate
activity: PubMed Pubstatus of Entrez
period: ?? --> 2001-03-07 10:00:00+0000
citedArtifact
identifier:
https://pubmed.ncbi.nlm.nih.gov/11232013,https://doi.org/10.1210/jcem.86.1.7157Titles
Type Language Text Primary title English Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
Abstracts
Text This study evaluated the efficacy and safety of rosiglitazone monotherapy in patients with type 2 diabetes. After a 4-week placebo run-in period, 493 patients with type 2 diabetes were randomized to receive rosiglitazone [2 or 4 mg twice daily (bd)] or placebo for 26 weeks. The primary end point was change in hemoglobin A(1c); other variables assessed included fasting plasma glucose, fructosamine, endogenous insulin secretion, urinary albumin excretion, serum lipids, and adverse events. Rosiglitazone (2 and 4 mg bd) decreased mean hemoglobin A(1c) relative to placebo by 1.2 and 1.5 percentage points, respectively, and reduced fasting plasma glucose concentrations relative to placebo by 3.22 and 4.22 mmol/L, respectively. Fasting plasma insulin and insulin precursor molecules decreased significantly. Homeostasis model assessment estimates indicate that rosiglitazone (2 and 4 mg bd) reduced insulin resistance by 16.0% and 24.6%, respectively, and improved ss-cell function over baseline by 49.5% and 60.0%, respectively. Urinary albumin excretion decreased significantly in the rosiglitazone (4 mg bd) group. There was no increase in adverse events with rosiglitazone. In the short-term, rosiglitazone is an insulin sensitizer that is effective and safe as monotherapy in patients with type 2 diabetes who are inadequately controlled by lifestyle interventions.
relatesTo
type: correction-in
classifier: Published Erratum
citation:
J Clin Endocrinol Metab 2001 Apr;86(4):1659
relatesTo
type: correction-in
classifier: Published Erratum
citation:
J Clin Endocrinol Metab. 2002 Feb;2(1):iv.
publicationForm
publishedIn
type: Periodical
identifier: Print ISSN Type/0021-972X, ISOAbbreviation/J Clin Endocrinol Metab, ISSN Linking/0021-972X, Medline Title Abbreviation/J Clin Endocrinol Metab, NLM Unique ID/0375362
title: The Journal of clinical endocrinology and metabolism
publisherLocation: United States
citedMedium: Print
volume: 86
issue: 1
articleDate: 2001-01
publicationDateText: 2001-Jan
language: English
pageString: 280-8
WebLocations
Classifier Url Abstract https://pubmed.ncbi.nlm.nih.gov/11232013/ classification
type: Publishing Model
classifier: Print
classification
type: Chemical
classifier: Blood Glucose, Hypoglycemic Agents, Thiazoles, Thiazolidinediones, Rosiglitazone
classification
type: MeSH heading
artifactAssessment: ArtifactAssessment: artifact[x] = this resource
classification
type: Publication type
classifier: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial
classification
type: Knowledge Artifact Type
classifier: Journal Article
artifactAssessment: Classifier added by Computable Publishing LLC
classification
type: Citation subset
classifier: IM
contributorship
complete: true
entry
contributor: Lebovitz HE
forenameInitials: HE
affiliation: Department of Medicine, State University of New York, Brooklyn, New York 11203, USA. hlebovitz@attglobal.net
entry
contributor: Dole JF
forenameInitials: JF
entry
contributor: Patwardhan R
forenameInitials: R
entry
contributor: Rappaport EB
forenameInitials: EB
entry
contributor: Freed MI
forenameInitials: MI
entry
contributor: Rosiglitazone Clinical Trials Study Group
Generated Narrative: Practitioner #contributor0
name: H E Lebovitz
Generated Narrative: Practitioner #contributor1
name: J F Dole
Generated Narrative: Practitioner #contributor2
name: R Patwardhan
Generated Narrative: Practitioner #contributor3
name: E B Rappaport
Generated Narrative: Practitioner #contributor4
name: M I Freed
Generated Narrative: Organization #contributor5
name: Rosiglitazone Clinical Trials Study Group
Generated Narrative: ArtifactAssessment #meshHeading0
artifact: Citation 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
content
type: components (if present) include qualifier codings
classifier: Aged
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Aged, 80 and over
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Blood Glucose
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: analysis
Components
Type Classifier is Major topic No content
type: components (if present) include qualifier codings
classifier: Diabetes Mellitus, Type 2
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: blood
Components
Type Classifier is Major topic No component
type: qualifier
classifier: drug therapy
Components
Type Classifier is Major topic Yes component
type: qualifier
classifier: physiopathology
Components
Type Classifier is Major topic No content
type: components (if present) include qualifier codings
classifier: Double-Blind Method
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Female
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Humans
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Hypoglycemic Agents
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: adverse effects
Components
Type Classifier is Major topic No component
type: qualifier
classifier: therapeutic use
Components
Type Classifier is Major topic Yes content
type: components (if present) include qualifier codings
classifier: Islets of Langerhans
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: drug effects
Components
Type Classifier is Major topic No component
type: qualifier
classifier: physiopathology
Components
Type Classifier is Major topic No content
type: components (if present) include qualifier codings
classifier: Male
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Middle Aged
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Rosiglitazone
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Single-Blind Method
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Thiazoles
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: adverse effects
Components
Type Classifier is Major topic No component
type: qualifier
classifier: therapeutic use
Components
Type Classifier is Major topic Yes content
type: components (if present) include qualifier codings
classifier: Thiazolidinediones
freeToShare: true
Components
Type Classifier qualifier is Major topic
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-12-19
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change